President, Mount Sinai Innovation Partners
Chief Commercial Innovation Officer, Mount Sinai Health System
Erik Lium, PhD, is the Chief Commercial Innovation Officer for the Mount Sinai Health System and the President of Mount Sinai Innovation Partners (MSIP). Dr. Lium is responsible for advancing Mount Sinai’s research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialization of Mount Sinai technologies, and fostering the development of startups to advance promising early-stage technologies.
Under Dr. Lium’s leadership and through Mount Sinai’s expansive network of industry partnerships and a vast array of innovators in the fields of drugs, devices, diagnostics, and digital health, Mount Sinai has become a global leader in the commercialization of healthcare technology which is reflected in its substantial portfolio of technologies in commercial development and the number of startup companies launched.
Dr. Lium participated in and/or led the creation of 29 public and private companies based on Mount Sinai technologies since 2016, current estimated equity value held by Mount Sinai is over $500M. The portfolio includes - but is not limited to - Sema4 (NASDAQ: SMFR), Renalytix (NASDAQ: RNLX), Trellus Health (LSE:TRLS), VericiDx (LON: VRCI), and PreciseDx.
Dr. Lium joined Mount Sinai as Vice President of MSIP in 2014 and was named Chief Commercial Innovation Officer and Executive Vice President in 2018. Earlier, he held positions at the University of California, San Francisco (UCSF), including Assistant Vice Chancellor of Innovation, Technology and Alliances; UCSF Principal Investigator for the Bay Area National Science Foundation I-Corps node; and Assistant Vice Chancellor of Research. He also served as Founder and President of LabVelocity Inc., an information services company focused on accelerating research and development in the life sciences.
Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.